CAR-T Meeting 2024 | Shallow WGS vs conventional cytogenetic analysis for diagnosing and stratifying MDS
Peter Vandenberghe, MD, UZ Leuven, Leuven, Belgium, comments on the possibility of using shallow whole-genome sequencing (WGS) in place of conventional cytogenetic analysis for diagnosing and stratifying myelodysplastic syndromes (MDS). Shallow WGS can be automated, reducing the time and cost of acquiring information regarding copy number abnormalities (gains or losses) from a sample. This technique can be performed using both bone marrow (BM) and peripheral blood (PB) samples, meaning that analysis from the PB can be used for non-invasive diagnosis of patients in clinical practice. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sponsorship or research funding: Janssen – Cilag, Pfizer;
Honoraria for advisory boards/meeting attendance support/consultancy/speaker fees: Bristol-Myers-Squibb, Gilead, Janssen-Cilag, Miltenyi Biotec, Novartis.
